Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in ...

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Presentation Highlights HyBryte Potential in CTCL In January 2025, Dr. Neal Bhatia presented at two dermatology ...

The latest update is out from PotlatchDeltic ( (PCH) ).

RICHMOND, Calif.-- (BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.

Positive topline data from the long-term OLE portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia presented as an oral presentation on March 30th at the 2025 Congress of ...

Key presentations highlight the Phase 3 trials of AXS-12 for narcolepsy, detailing its effects on symptom severity and functional impairment, while also addressing real-world applications of ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

First Quarter 2025 Financial Highlights Cash Position: Cash and cash equivalents, and short-term investments of $136.5 million as of March 31, 2025, compared with $147.3 million as of December 31 ...

Poster Presentation #21 (Abstract #11538): Personalized Radiation Strategies in Soft Tissue Sarcoma Title: MicroRNA-based Biomarkers of Outcome in Soft Tissue Sarcoma Treated with Hypofractionated ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 25, 2025-- ...

Upcoming oral presentation: "INB-200: Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance ...